The significant decrease in the α1(V) chain after cutaneous SSc fibroblast transfection with siRNA COL5A2 provides a rationale for the future development of a gene therapy that would have the potential for the transcriptional inhibition of mRNA to Col V alpha chains which is a possible therapeutic strategy in the treatment of SSc. Here, COL5A2 is linked to systemic sclerosis.